PubMed Health⌕ Search

PubMed · 8024145

New inhaled anesthetics.

Abstract

Desflurane and sevoflurane provide one clear advantage over other currently available potent inhaled anesthetics. Their lower solubilities permit a more precise control over the delivery of anesthesia and a more rapid recovery from anesthesia. Most of their other properties reflect similar properties of their predecessors--with a few exceptions. Indeed, at concentrations of 1 MAC or less, the pharmacologic properties of these two agents differ little if at all. However, in contrast to desflurane, at concentrations exceeding 1 MAC sevoflurane has little or no respiratory irritant properties and may be used to rapidly induce anesthesia. Neither anesthetic seems to materially affect heart rate at concentrations lower than MAC, but at higher concentrations desflurane, but not sevoflurane, may increase heart rate. Desflurane strongly resists biodegradation and degradation by soda lime, whereas sevoflurane is vulnerable to degradation and the degradation by soda lime or Baralyme produces a toxic product. Thus, neither of these new anesthetics can be said to be ideal, but each may be a step in that direction.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E I Eger. 1994. New inhaled anesthetics.. https://doi.org/10.1097/00000542-199404000-00024

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗